FOLD
Price
$5.73
Change
-$0.20 (-3.37%)
Updated
Jun 30, 04:59 PM (EDT)
Capitalization
1.83B
31 days until earnings call
MNKD
Price
$3.67
Change
-$0.09 (-2.39%)
Updated
Jun 30, 02:16 PM (EDT)
Capitalization
1.14B
37 days until earnings call
Interact to see
Advertisement

FOLD vs MNKD

Header iconFOLD vs MNKD Comparison
Open Charts FOLD vs MNKDBanner chart's image
Amicus Therapeutics
Price$5.73
Change-$0.20 (-3.37%)
Volume$255.69K
Capitalization1.83B
MannKind
Price$3.67
Change-$0.09 (-2.39%)
Volume$300
Capitalization1.14B
FOLD vs MNKD Comparison Chart in %
Loading...
FOLD
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
MNKD
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
FOLD vs. MNKD commentary
Jun 30, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is FOLD is a StrongBuy and MNKD is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 30, 2025
Stock price -- (FOLD: $5.93 vs. MNKD: $3.76)
Brand notoriety: FOLD and MNKD are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: FOLD: 185% vs. MNKD: 421%
Market capitalization -- FOLD: $1.83B vs. MNKD: $1.14B
FOLD [@Biotechnology] is valued at $1.83B. MNKD’s [@Biotechnology] market capitalization is $1.14B. The market cap for tickers in the [@Biotechnology] industry ranges from $299.85B to $0. The average market capitalization across the [@Biotechnology] industry is $2.3B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

FOLD’s FA Score shows that 0 FA rating(s) are green whileMNKD’s FA Score has 0 green FA rating(s).

  • FOLD’s FA Score: 0 green, 5 red.
  • MNKD’s FA Score: 0 green, 5 red.
According to our system of comparison, MNKD is a better buy in the long-term than FOLD.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

FOLD’s TA Score shows that 4 TA indicator(s) are bullish while MNKD’s TA Score has 5 bullish TA indicator(s).

  • FOLD’s TA Score: 4 bullish, 3 bearish.
  • MNKD’s TA Score: 5 bullish, 3 bearish.
According to our system of comparison, MNKD is a better buy in the short-term than FOLD.

Price Growth

FOLD (@Biotechnology) experienced а +5.14% price change this week, while MNKD (@Biotechnology) price change was -1.31% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +3.68%. For the same industry, the average monthly price growth was +32.84%, and the average quarterly price growth was +6.72%.

Reported Earning Dates

FOLD is expected to report earnings on Jul 31, 2025.

MNKD is expected to report earnings on Aug 06, 2025.

Industries' Descriptions

@Biotechnology (+3.68% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
FOLD($1.83B) has a higher market cap than MNKD($1.14B). FOLD YTD gains are higher at: -37.049 vs. MNKD (-41.524). MNKD has higher annual earnings (EBITDA): 82.6M vs. FOLD (53.6M). FOLD has more cash in the bank: 251M vs. MNKD (182M). MNKD has less debt than FOLD: MNKD (47.2M) vs FOLD (443M). FOLD has higher revenues than MNKD: FOLD (543M) vs MNKD (298M).
FOLDMNKDFOLD / MNKD
Capitalization1.83B1.14B160%
EBITDA53.6M82.6M65%
Gain YTD-37.049-41.52489%
P/E RatioN/A37.60-
Revenue543M298M182%
Total Cash251M182M138%
Total Debt443M47.2M939%
FUNDAMENTALS RATINGS
FOLD vs MNKD: Fundamental Ratings
FOLD
MNKD
OUTLOOK RATING
1..100
5050
VALUATION
overvalued / fair valued / undervalued
1..100
64
Fair valued
48
Fair valued
PROFIT vs RISK RATING
1..100
10056
SMR RATING
1..100
93100
PRICE GROWTH RATING
1..100
8888
P/E GROWTH RATING
1..100
10098
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

MNKD's Valuation (48) in the Biotechnology industry is in the same range as FOLD (64). This means that MNKD’s stock grew similarly to FOLD’s over the last 12 months.

MNKD's Profit vs Risk Rating (56) in the Biotechnology industry is somewhat better than the same rating for FOLD (100). This means that MNKD’s stock grew somewhat faster than FOLD’s over the last 12 months.

FOLD's SMR Rating (93) in the Biotechnology industry is in the same range as MNKD (100). This means that FOLD’s stock grew similarly to MNKD’s over the last 12 months.

FOLD's Price Growth Rating (88) in the Biotechnology industry is in the same range as MNKD (88). This means that FOLD’s stock grew similarly to MNKD’s over the last 12 months.

MNKD's P/E Growth Rating (98) in the Biotechnology industry is in the same range as FOLD (100). This means that MNKD’s stock grew similarly to FOLD’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
FOLDMNKD
RSI
ODDS (%)
N/A
Bullish Trend 4 days ago
78%
Stochastic
ODDS (%)
Bullish Trend 4 days ago
72%
Bullish Trend 4 days ago
78%
Momentum
ODDS (%)
Bearish Trend 4 days ago
78%
Bearish Trend 4 days ago
74%
MACD
ODDS (%)
Bullish Trend 4 days ago
66%
Bullish Trend 4 days ago
76%
TrendWeek
ODDS (%)
Bullish Trend 4 days ago
68%
Bearish Trend 4 days ago
78%
TrendMonth
ODDS (%)
Bearish Trend 4 days ago
78%
Bearish Trend 4 days ago
76%
Advances
ODDS (%)
Bullish Trend 4 days ago
68%
Bullish Trend 28 days ago
81%
Declines
ODDS (%)
Bearish Trend 13 days ago
78%
Bearish Trend 4 days ago
80%
BollingerBands
ODDS (%)
Bullish Trend 4 days ago
77%
Bullish Trend 4 days ago
84%
Aroon
ODDS (%)
Bearish Trend 4 days ago
78%
Bearish Trend 4 days ago
71%
View a ticker or compare two or three
Interact to see
Advertisement
FOLD
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
MNKD
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
FGLGX25.790.19
+0.74%
Fidelity Series Large Cap Stock
VELIX17.200.12
+0.70%
VELA Large Cap Plus I
ATWAX24.110.14
+0.58%
AB Tax-Managed Wealth Apprec Strat A
EAISX16.550.08
+0.49%
Parametric International Equity A
IOGYX36.34-1.40
-3.71%
Invesco Gold & Special Minerals R5

MNKD and

Correlation & Price change

A.I.dvisor indicates that over the last year, MNKD has been loosely correlated with VCYT. These tickers have moved in lockstep 44% of the time. This A.I.-generated data suggests there is some statistical probability that if MNKD jumps, then VCYT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To MNKD
1D Price
Change %
MNKD100%
-0.27%
VCYT - MNKD
44%
Loosely correlated
+2.13%
LXRX - MNKD
42%
Loosely correlated
-11.66%
INSM - MNKD
40%
Loosely correlated
-2.21%
BLUE - MNKD
38%
Loosely correlated
N/A
UTHR - MNKD
38%
Loosely correlated
N/A
More